(AOF) – Korian, the leading European care group serving the elderly and fragile, has unveiled its half-year results, posting a net result, group share of 12.9 million euros against 43.7 million a year earlier . Its Ebitda stood at 491.1 million euros against 275.5 million a year ago. The group recorded growth of 5.5% in its turnover, to 2.224 billion euros. Operating income came to 131 million euros against 118.6 million euros.
These results reflect a solid performance supported by investments in HR and the transformation of the network.
“The fundamental actions undertaken since 2019 to strengthen the attractiveness of our professions are bearing fruit: thanks to the investment made in work-study and professional promotion, we can already cover half of our needs in permanent recruitments and continue to strengthen our management ratios for the benefit of better support. By relying on a dynamic social dialogue and, henceforth, on the development of employee shareholding, we will continue to reposition the group and its transformation into a company with a mission, dedicated to the prevention and support of all situations of fragility, as close as possible to the territories”, commented Sophie Boissard, Chief Executive Officer of the group.
The group expects organic growth of close to 6% for 2022.
Korian will publish its revenue for the third quarter of 2022 on October 27.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.